Tag: Jazz Pharmaceuticals

Epidiolex delivers positive results for a third rare condition called TSC

Epidiolex reports positive results for its drug when treating tuberous sclerosis complex (TSC) a rare genetic condition. The condition causes mostly benign tumors to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs and is a leading cause of genetic epilepsy. Epidiolex was the leading medical marijuana drug […]

Jazz Pharmaceuticals posts $215 million in net income for third quarter

Ireland-based Jazz Pharmaceuticals (Nasdaq: JAZZ), the makers of Epidiolex, reported net income in the third quarter this year of $215 million, with revenue up 9% year-over-year. That brings the company’s total net income for the year so far to $369 million on revenue of $2.9 billion. The company’s high-profile cannabis-based drug, Epidiolex, accounted for $251.5 […]